Search clinical trials for: Dolutegravir / Lamivudine Pill

Total 3348 results

Erasmus Medical Center
Catharina Ziekenhuis Eindhoven; Maasstad Hospital, Rotterdam; MC Haaglanden,... and other collaborators

Recruiting

Defining the Potency of DTG/3TC for Suppressed HIV Patients in Real-life: the DUALING Study (DUALING)

Hiv

Netherlands
Fundacion IDEAA
ViiV Healthcare

Completed

Efficacy of Dolutegravir Plus Lamivudine in HIV-1-infected Treatment-naïve Adults Without a Baseline Genotyping Test (D2ARLING)

Hiv | HIV-1-infection

Argentina
Charlotte-Paige Rolle, MD
ViiV Healthcare

Completed

Efficacy of Switching to DTG/3TC in Virologically-suppressed Adults Currently on B/F/TAF (DYAD)

HIV I Infection

United States
Fundacion SEIMC-GESIDA
ViiV Healthcare

Active, not recruiting

DTG/3TC vs. BIC/FTC/TAF Maintenance Therapy in People Living With HIV: (PASO-DOBLE)

HIV-1-infection

Spain
Fundación Huésped
ViiV Healthcare

Completed

Dolutegravir-Lamivudine as Dual Therapy in Naive HIV-Infected Patients: A Pilot Study (PADDLE)

HIV-1 Infection

Argentina
Thomas Benfield

Recruiting

Changes in Weight, Body Composition and Cardiac Risk After Discontinuing Abacavir Treatment in HIV-infected Individuals (AVERTAS-1)

Cardiovascular Diseases | HIV Infections | Hiv | Weight Change, Body | HIV Lipodystrophy | HIV Cardiomyopathy

Denmark
ViiV Healthcare
GlaxoSmithKline

Completed

Relative Bio-availability Study of Dolutegravir and Lamivudine Fixed Dose Combinations

Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare
GlaxoSmithKline

Completed

Bioequivalence Study of Fixed Dose Versus Single Entities of Dolutegravir and Lamivudine

Infection, Human Immunodeficiency Virus

United States
Shanghai Public Health Clinical Center

Not yet recruiting

Efficacy and Tolerability of DTG Plus 3TC in HIV Infected Adults With Virologically Suppression and TDF Toxicity

Acquired Immunodeficiency Syndrome
Fundación Huésped
ViiV Healthcare; Federal University of Bahia

Recruiting

Dolutegravir-Lamivudine for naïve HIV-Infected Patients With ≤200 CD4/mm3 (DOLCE)

HIV-1-infection

Brazil, Argentina
Societa' Italiana Di Malattie Infettive E Tropicali

Recruiting

Early DOlutegravir/LAmivudine Switching After Virological Suppression (EDOLAS Study) (EDOLAS)

HIV-1-infection

Italy
Mylan Inc.
ViiV Healthcare

Completed

Abacavir, Dolutegravir and Lamivudine Dispersible Tablets (60 mg/5 mg/30 mg)

HIV-1-infection

Canada
Saint Michael's Medical Center
ViiV Healthcare

Active, not recruiting

Switch to DOVATO in Patients Suppressed on Biktarvy (SOUND) (Sound)

Human Immunodeficiency Virus

United States
ViiV Healthcare

Completed

Rapid Test and Treat Dolutegravir Plus Lamivudine Study in Newly Diagnosed Human Immunodeficiency Virus (HIV)-1 Infected Adults

HIV Infections

United States
ANRS, Emerging Infectious Diseases
MSD France

Not yet recruiting

DORAvirine Versus DOlutegravir Based Antiretroviral Regimens in Treatment-naïve People Living With HIV-1 Infection (ELDORADO)

HIV-1-infection

Brazil, Cambodia, Cameroon, Côte D'Ivoire, France, Mozambique
University of Liege

Active, not recruiting

Impact of DOlutegravir+Lamivudine Simplification on HIV-1 Reservoirs (IDOLTIB)

HIV Infections

Belgium
Pedro Cahn
ViiV Healthcare

Withdrawn

Dolutegravir-Lamivudine as Dual Therapy in naïve HIV-Infected Patients With Documented M184V Mutation:A Pilot Study (PADDLE184V)

HIV-1 Infection

Argentina
National Institute of Allergy and Infectious Diseases...
Eunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaborators

Completed

The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age

HIV Infections

United States, South Africa, Thailand, Botswana
ANRS, Emerging Infectious Diseases
ViiV Healthcare

Completed

A Trial Evaluating Maintenance Therapy With Lamivudine (Epivir®) and Dolutegravir (Tivicay®) in Human Immunodeficiency Virus 1 (HIV-1) Infected Patients Virologically Suppressed With Triple Highly Active Antiretroviral Therapy (HAART) (ANRS 167 Lamidol)

HIV-1 Infection

France
University Hospital Virgen de las Nieves

Unknown

Real Life Study of Dolutegravir Plus Lamivudine in HIV-1-Infected Treatment-Naive Patients (DOLAVI)

HIV-1-infection

Spain
Instituto de Investigación Sanitaria de la Fundación...

Completed

REal-Life Cohort With DOlutegravir + LAmivudina (REDOLA)

HIV-1-infection

Spain
Fundação Bahiana de Infectologia
GlaxoSmithKline

Completed

DTG Plus 3TC for Prophylaxis of Mother-to-child Transmission of HIV Infection in Pregnant Women (PREGNANCY)

HIV Infections | Pregnancy Related | Mother to Child Transmission

Brazil
Instituto de Investigación Hospital Universitario...

Unknown

Antiretroviral Treatment Guided by Proviral Genotype: Pilot Trial of Proof of Concept.

HIV-1-infection

Spain
Nantes University Hospital

Completed

Multicentric Open-label Study of Switch From Abacavir/Lamivudine Fixed Dose Combination Plus Nevirapine to Abacavir/Lamivudine/Dolutegravir in Virologically Suppressed HIV-1 Infected Adults (SWAD) (SWAD)

HIV-1 Infection

France
Macquarie University, Australia
King's College London; Stichting TRICALS Foundation

Recruiting

Triumeq in Amyotrophic Lateral Sclerosis (LIGHTHOUSE II)

Amyotrophic Lateral Sclerosis

Australia, New Zealand
PENTA Foundation
Baylor College of Medicine; University Hospital Birmingham NHS Foundation Trust and other collaborators

Recruiting

DTG/3TC Fixed Dose Formulations for the Maintenance of Virological Suppression in Children With HIV Infection Aged 2 to <15 Years Old (D3 (Penta21))

HIV Infections

Spain, United Kingdom, Thailand, South Africa, Uganda
University College Dublin
ViiV Healthcare; Mater Misericordiae University Hospital

Unknown

Triumeq As an Integrase Single Tablet Regimen in People With HIV Who Inject Drugs (TAISTR)

Human Immunodeficiency Virus

Ireland
Centre Hospitalier Régional d'Orléans

Terminated

Study to Evaluate the Efficacy of MONotherapy of TiviCAY® Versus a Triple Therapy in HIV-1-infected Patients (MONCAY)

HIV

France
Fundacion SEIMC-GESIDA
ViiV Healthcare

Completed

Lamivudine/Dolutegravir in Virologically Suppressed Subjects With Expected or Confirmed Resistance to Lamivudine (VOLVER)

HIV Infections

Spain
ViiV Healthcare

Completed

'COMBINE-2': Real-world Evidence for Effectiveness of Two Drug Regimen, Antiretroviral Therapy With Integrase Inhibitors Plus a Reverse Transcriptase Inhibitor

HIV Infections

Spain
St Stephens Aids Trust
ViiV Healthcare

Completed

SSAT064: Pharmacokinetics of Abacavir/Lamivudine/Dolutegravir in HIV Patients of 60 Years and Over

HIV

United Kingdom
ViiV Healthcare
GlaxoSmithKline; Shionogi

Completed

A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)

Infection, Human Immunodeficiency Virus I

United States, Spain, Germany, Australia, Canada, Belgium, Denmark, Netherlands, United Kingdom, France, Italy, Romania
ViiV Healthcare
GlaxoSmithKline; Shionogi

Completed

Relative Bioavailability Study of Two New Dolutegravir/Abacavir/Lamivudine Fixed Dose Combination Tablets

Healthy Subjects | Infection, Human Immunodeficiency Virus

United States
Insel Gruppe AG, University Hospital Bern
University of Bern; Center for Primary Care and Public Health (Unisante), University...

Enrolling by invitation

B-free Multistage Trial (B-free)

HIV | Drug Resistance | Drug Drug Interaction

Switzerland
Neuroscience Trials Australia
Macquarie University, Australia; Calvary Health Care Bethlehem; Westmead Hosptial and other collaborators

Completed

Safety and Tolerability of Antiretroviral (Triumeq) in Patients With Amyotrophic Lateral Sclerosis (ALS). (Lighthouse)

Amyotrophic Lateral Sclerosis

Australia
Babafemi Taiwo
ViiV Healthcare

Completed

Dolutegravir Antiretroviral Strategy to Promote Improvement and Reduce Drug Exposure (ASPIRE)

HIV Infection

United States
ViiV Healthcare
GlaxoSmithKline; Shionogi

Completed

Evaluation of the Bioequivalence of a Combined Formulated Tablet

Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare
Syneos Health

Terminated

A Clinical Trial of GSK3640254 + Dolutegravir (DTG) in Human Immunodeficiency Virus-1 Infected Treatment-naive Adults (DYNAMIC)

HIV Infections

Germany, Spain, United States, Canada, France, Italy, South Africa, Argentina, Portugal, Puerto Rico
University of KwaZulu
Centre for the AIDS Programme of Research in South Africa

Recruiting

Pharmacokinetics of Twice or Once Daily DTG (50mg) in Children With HIV and TB (ORCHID)

Tuberculosis | Hiv

South Africa
Thomas Benfield

Recruiting

Changes in Weight, Body Composition and Metabolic Parameters After Discontinuing Dolutegravir or Tenofovir Disproxil (AVERTAS-2)

HIV Infections | Obesity | Renal Insufficiency | Osteoporosis | Hiv | Weight Gain | HIV Lipodystrophy

Denmark
Philip Grant

Withdrawn

Effect of Reducing Nucleotide Exposure on Bone Health (ReNew) (ReNew)

HIV/AIDS | Osteopenia | HIV-1-infection

United States
ViiV Healthcare
GlaxoSmithKline

Completed

An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir (DTG) Plus Lamivudine (3TC) With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Participants (Gemini 2)

HIV Infections | Infection, Human Immunodeficiency Virus

United States, Argentina, Spain, Germany, Belgium, Australia, Canada, United Kingdom, Italy, Romania, Taiwan, Russian Federation, Mexico, France, Switzerland, Peru, Poland, Portugal
ViiV Healthcare
GlaxoSmithKline

Completed

A Study to Determine Safety and Efficacy of Dolutegravir/Abacavir/Lamivudine (DTG/ABC/3TC) in Human Immunodeficiency Virus (HIV)-1 Infected Antiretroviral Therapy (ART) Naïve Women (ARIA)

HIV Infections | Infection, Human Immunodeficiency Virus

United States, France, Spain, United Kingdom, Canada, Thailand, Italy, Portugal, Russian Federation, Mexico, Argentina, South Africa, Puerto Rico
ViiV Healthcare

Completed

A Food-effect Study of the Pediatric Dispersible Tablet Formulations of TRIUMEQ® and DOVATO® in Healthy Adult Participants

HIV Infections

United States
ViiV Healthcare
GlaxoSmithKline; PPD

Completed

An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 1)

HIV Infections | Infection, Human Immunodeficiency Virus

Taiwan, France, Germany, Belgium, United States, Canada, Netherlands, Spain, Korea, Republic of, Italy, Australia, United Kingdom, Russian Federation, Portugal, Argentina, South Africa, Romania, Mexico
University of North Carolina, Chapel Hill
ViiV Healthcare

Completed

Safety and Efficacy of Fixed Dose Combination Dolutegravir/Abacavir/Lamivudine FDC Initiated During Acute HIV Infection (PHI-05)

HIV | Acute HIV Infection

United States
Azienda Ospedaliera Universitaria Senese
Catholic University of the Sacred Heart; Ospedale Policlinico San Martino; Azienda... and other collaborators

Unknown

Neurological Monitoring in Patients Switching From Dolutegravir Based Regimen to Bictegravir Based Regimen (DOBINeuro)

HIV-1-infection

Italy
Centre for the AIDS Programme of Research in South...
Johns Hopkins University; National Institute of Allergy and Infectious Diseases... and other collaborators

Active, not recruiting

INSTI's For The Management of HIV-associated TB (INSIGHT)

HIV/AIDS | Tuberculosis, Pulmonary

South Africa
Cristina Mussini

Unknown

Evaluating Inflammatory and Immunological Changes of HIV-positive Patients Switching to DTG Dual Regimen Compared to Those Switching to a Triple Drugs Regimen (B/F/TAF)

HIV Infections
ANRS, Emerging Infectious Diseases
Mylan Laboratories

Active, not recruiting

ANRS 12372 MODERATO Study (MODERATO)

HIV-1-infection

Côte D'Ivoire, Burkina Faso, Cameroon

Search clinical trials for: Dolutegravir / Lamivudine Pill

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Turkmenistan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations